Zuellig Pharma, a prominent healthcare solutions company in Asia, has announced the acquisition of the Zam-Buk and Vapex consumer healthcare brands from Bayer Consumer Care AG. This strategic move, effective from 9 February 2026, covers the markets of Thailand, Singapore, Indonesia, Malaysia, and Brunei. The acquisition aims to bolster Zuellig Pharma’s consumer healthcare portfolio across Asia.
Zam-Buk, an ointment first launched in 1902, is renowned for providing temporary relief from pain and itch, including insect bites. Vapex, a nasal inhaler introduced in 1917, is well-known for alleviating nasal congestion, particularly in Thailand. Both brands have maintained strong brand equity and consumer trust over the years.
This acquisition aligns with Zuellig Pharma’s strategic priority to scale its consumer healthcare offerings in the region. It follows the company’s previous acquisition of Propan in the Philippines, further solidifying its commitment to building a robust platform for everyday healthcare products. John Graham, CEO of Zuellig Pharma, stated, “Zam-Buk and Vapex are enduring brands with deep heritage and trust in the communities they serve. By combining the brands’ legacy with Zuellig Pharma’s regional commercial capabilities and local market expertise, we aim to expand distribution and access across all relevant retail channels in the region.”
Zuellig Pharma, founded a century ago, has grown into a multibillion-dollar enterprise, serving over 200,000 medical facilities across 18 markets with more than 12,000 employees. The acquisition of Zam-Buk and Vapex is expected to enhance the company’s reach and accessibility in the consumer healthcare sector.
